CN111867678B - 治疗黑色素瘤的方法 - Google Patents

治疗黑色素瘤的方法 Download PDF

Info

Publication number
CN111867678B
CN111867678B CN201980020523.3A CN201980020523A CN111867678B CN 111867678 B CN111867678 B CN 111867678B CN 201980020523 A CN201980020523 A CN 201980020523A CN 111867678 B CN111867678 B CN 111867678B
Authority
CN
China
Prior art keywords
melanoma
tumor
cells
mice
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980020523.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111867678A (zh
Inventor
卡罗·马切蒂
查尔斯·A·迪纳雷罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of CN111867678A publication Critical patent/CN111867678A/zh
Application granted granted Critical
Publication of CN111867678B publication Critical patent/CN111867678B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980020523.3A 2018-03-21 2019-03-18 治疗黑色素瘤的方法 Active CN111867678B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
US62/645,999 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (2)

Publication Number Publication Date
CN111867678A CN111867678A (zh) 2020-10-30
CN111867678B true CN111867678B (zh) 2023-04-28

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980020523.3A Active CN111867678B (zh) 2018-03-21 2019-03-18 治疗黑色素瘤的方法

Country Status (7)

Country Link
US (1) US11857529B2 (https=)
EP (1) EP3768384B1 (https=)
JP (1) JP7229565B2 (https=)
CN (1) CN111867678B (https=)
CA (1) CA3094307A1 (https=)
MX (1) MX2020009552A (https=)
WO (1) WO2019182981A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
WO2021076444A1 (en) 2019-10-14 2021-04-22 Olatec Therapeutics Llc Methods for treating breast cancer
JP2024534040A (ja) * 2021-08-19 2024-09-18 オラテック セラピューティクス， インコーポレイティド パーキンソン病の治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103260613A (zh) * 2010-12-15 2013-08-21 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的3-甲磺酰基丙腈
CN104334165A (zh) * 2012-06-05 2015-02-04 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的药物组合物
CN104411303A (zh) * 2012-06-05 2015-03-11 欧拉泰克工业有限责任公司 用于治疗皮肤炎性疾病的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
CA3021349A1 (en) * 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
EP3565540B1 (en) * 2017-01-06 2023-12-06 Olatec Therapeutics LLC A pharmaceutical composition for use in treating cardiovascular diseases
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103260613A (zh) * 2010-12-15 2013-08-21 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的3-甲磺酰基丙腈
CN104334165A (zh) * 2012-06-05 2015-02-04 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的药物组合物
CN104411303A (zh) * 2012-06-05 2015-03-11 欧拉泰克工业有限责任公司 用于治疗皮肤炎性疾病的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation;Carlo Marchetti等;《PNAS》;第115卷(第115期);E1530-E1539 *
The NLRP3 inflammasome, a target for therapy in diverse disease states;Cool, Graham P等;《Eur.J.Immunol》;第40卷(第40期);631-634 *
Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome;Israr Ahmad等;《Toxicology and Applied Pharmacology》;第270卷(第270期);70-76 *

Also Published As

Publication number Publication date
US11857529B2 (en) 2024-01-02
CA3094307A1 (en) 2019-09-26
WO2019182981A1 (en) 2019-09-26
JP7229565B2 (ja) 2023-02-28
EP3768384A1 (en) 2021-01-27
US20200405681A1 (en) 2020-12-31
MX2020009552A (es) 2020-10-05
EP3768384A4 (en) 2021-11-17
JP2021518374A (ja) 2021-08-02
EP3768384B1 (en) 2025-06-25
CN111867678A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
JP7175334B2 (ja) 免疫刺激剤による癌治療
BR112019024135A2 (pt) Terapias de combinação para o tratamento de câncer
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
US11857529B2 (en) Methods for treating melanoma
CN112807434B (zh) Perk抑制剂在制备肝癌药物的增效剂中的应用
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療
AU2016371598A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
US12582628B2 (en) Methods for treating breast cancer
EP3664786B1 (en) Method for treating schnitzler's syndrome
JP7648155B2 (ja) プロカスパーゼ‐３の活性化及びがんの治療のための免疫療法
TW201932119A (zh) 膽道癌用抗腫瘤劑和膽道癌的處理方法
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
Niijima et al. Intravesical treatment of bladder cancer with recombinant human interferon-β: Intravesical GKT-β Chemotherapy Research Group (Chairman: Tadao Niijima)
US20240358669A1 (en) Methods for treating pancreatic cancer
WO2026035767A1 (en) Methods for treating melanoma metastasis to liver and lungs
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
CN118718000A (zh) 药物组合物及其在制备治疗肾癌的药物中的用途
HK40096805A (zh) 用於组合疗法的患者的选择
TW202139992A (zh) 用於癌症治療之醫藥組合
KR20200124661A (ko) 종양 성장을 감소시키기 위한 미나프린의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant